RxDoctor Payments Data

Pedram Enayati, MD

Internal Medicine · Beverly Hills, CANPI 1841403029

Payments from drug & device makers

$1,074,961in general payments, 2019–2025

Across 1,649 payments — averaging $651.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$390K
  • AbbVie$344K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$123K
  • Janssen Research & Development, LLC$116K
  • Bausch Health US, LLC$31K
  • Sanofi US Services Inc.$23K
  • plus $48K from 48 others
$23,484in research payments, 2019–2025

Across 2 payments — averaging $11,742 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$23K

What the payments were for

  • Consulting fees$920%
  • Speaking & faculty fees$147,77579%
  • Travel & lodging$10,1445%
  • Food & beverage$27,98515%
  • Education$3440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.34$390,104
AbbVie(2 entities)344$344,496
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC583$122,684
Janssen Research & Development, LLC14$116,176
Bausch Health US, LLC7$30,618
Sanofi US Services Inc.2$23,219
Gilead16$23,215
Ironwood Pharmaceuticals, Inc43$9,404
Redhill Biopharma Inc.21$2,594
Johnson & Johnson(2 entities)111$2,348
QOL Medical, LLC49$1,396
Takeda Pharmaceuticals U.S.A., Inc.92$1,360
Sanofi24$769
Pfizer49$695
Ardelyx, Inc.36$606
Bristol Myers Squibb35$419
AstraZeneca5$414
Nestle Healthcare Nutrition Inc.17$408
Intercept Pharmaceuticals, Inc.17$388
Merck17$358
Alnylam Pharmaceuticals Inc.10$308
Regeneron Healthcare Solutions, Inc.12$276
Aimmune Therapeutics, Inc.10$267
Daiichi Sankyo Inc.16$258
Phathom Pharmaceuticals, Inc.7$190
Romark Laboratories, LC6$180
Ferring Pharmaceuticals Inc.4$153
Madrigal Pharmaceuticals6$150
Braintree Laboratories, Inc.6$132
Amgen6$132
Shionogi Inc5$124
E.r. Squibb & Sons, L.L.C.1$122
Lundbeck LLC5$113
Nevro Corp.3$102
Ipsen Biopharmaceuticals, Inc3$84
Lilly USA, LLC3$82
Alfasigma USA, Inc.6$81
Mallinckrodt Hospital Products Inc.2$65
Boston Scientific3$60
Merz Pharmaceuticals, LLC2$53
Endo Pharmaceuticals Inc.3$52
Medtronic1$47
Perspectum Diagnostics Ltd1$43
Capsovision, Inc.2$40
Shire North American Group Inc1$23
Meridian Bioscience Inc.1$22
Novo Nordisk1$21
Impel Pharmaceuticals Inc.1$19
Acell, Inc.1$17
Concordia Pharmaceuticals Inc.1$16
Ortho Dermatologics, A Division Of Bausch Health US, LLC1$16
Almatica Pharma LLC1$16
Vivus LLC1$14
Upsher-smith Laboratories LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,074,961 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,069,981
Medicare patients
1,493
Services billed
10,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin38$86,094
LinzessLinaclotide77$64,587
CreonLipase/Protease/Amylase39$36,143
Dexlansoprazole DrDexlansoprazole27$9,483
Mesalamine15$8,941
Famotidine199$1,879
Omeprazole189$1,579
Dicyclomine Hcl59$593
Pantoprazole Sodium34$522
Neomycin Sulfate38$506
Desipramine Hcl15$384
Lansoprazole16$378
Sucralfate18$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$344,496$100,729116 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$122,684$86,09438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →